In the three months since Chandler, Arizona based Insys Therapeutics had its initial public offering Insys stock has been on the rise with a gain of over 120% from its original offering price.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company’s lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved. (Source: InsysRx.com)
Following its first quarterly report (Q2 2013) shares climbed by double-digits for after the company posted strong second-quarter results. [Insys Therapeutics Inc (NASDAQ: INSY )]
Seeking Alpha shared Insys Therapeutics: A Profitable Pharmaceutical Company With Great Potential Growth and posted the transcript of the Q2 call transcript here.
Replays are available from 2013 presentations by Insys at both the JMP Healthcare Conference
(July 9-10, 2013) and the Wells Fargo Securities 2013 Healthcare Conference (June 18, 2013). To learn more visit http://www.insysrx.com/investors/events/